iPSC derived artificial immature blood cells

MiCAN Technologies has technologies and licenses to produce high function human myeloid lineage cells (Mylc) from human iPS cells. The development and the feasibility studies to launch the cMylc has been conducted with a collaboration to the Research Institute for Microbial Diseases at Osaka University.

AdobeStock_198333071.jpeg

Business Information:

Name of the company:

MiCAN Technologies

Year of establishment:

2016

Location of the headquarters:

Kyoto, JP

Other key location(s):

Kobe, JP

Spinout from:

Independent

Year of establishment:

2016

MiCAN develops iPS-derived myeloid (immature dendritic cells) to be applied for virus research (including dengue and COVID-19) as well as for drug safety applications.

Company website:

MiCAN

Technology validation:

ビジネスミーティング

Technology readiness level (TRL)

7

CEO message:

Value if IP (patents)

MiCAN is looking for global R&D partners to evaluate our iPS derived dendric myeloid cells in the applications of dengue virus and COVID-19 (SARS-CoV-2) research. Also looking for global supply chain partners (distributors) to handle our ready-to-use kit accessible to the global scientists.

No data

creative innovation success.jpg

Current business stage:

Spinout / Seed fund stage

Next investment required:

Target exit style:

IPO in other country

Clinical study level (if relevant):

Pre-clinical

Kazuo Miyazaki

Technical literatures:
Biospire's roles:
    Global business development, alliance with international academia, etc.